Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1485 • ACR Convergence 2022
Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus
Mark Jensen¹, Ilona Nln¹, Taro Iwamoto², Jessica Dorschner³, Danielle Vsetecka³, Jacqueline Paredes¹, Ruth Fernandez Ruiz⁴, Theresa Wampler Muskardin⁵ and Timothy Niewold¹, ¹Hospital for Special Surgery, New York, NY, ²Chiba University, New York, NY, ³Mayo Clinic, Rochester, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Colton Center for Autoimmunity, NYU School of Medicine, New York, NY
Background/Purpose: To characterize regulatory surface receptors on blood plasmacytoid dendritic cells (PDCs) of lupus patients and controls to determine if receptor expression and function associates…
Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Brian J. Mog¹, Elana R. Shaw¹, Michael S. Hwang¹, Alexander H. Pearlman¹, Sarah R. DiNapoli¹, Suman Paul¹, Chetan Bettegowda¹, Nickolas Papadopoulos¹, Sandra B. Gabelli¹, Michelle Petri², Antony Rosen¹, Shibin Zhou¹, Kenneth W. Kinzler¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
Abstract Number: 1725 • ACR Convergence 2022
Sex Differences in Autoimmune Pathogenesis and Systemic Response to High Fat Diet in Lupus-prone Mice
Gitanjali Lobo¹, Juan Meng², Xuhua Shi², Ronak Patel³, Laura Rivers⁴, Chad Hille⁵, Robert Quinet⁶, William Davis⁷, Jerald Zakem⁸, Chandana Keshavamurthy⁹, Tamika Webb-Detiege¹⁰, Zongbing You² and Xin Zhang¹¹, ¹Ochsner Clinic Foundation, Metairie, LA, ²Tulane University, New Orleans, LA, ³Ochsner, New Orleans, LA, ⁴Ochsner Medical Center, River Ridge, LA, ⁵Ochsner Clinic Foundation, New Orleans, LA, ⁶Ochsner Health, River Ridge, LA, ⁷Ochsner Medical Center, New Orleans, LA, ⁸Ochsner Health Systems, Metairie, LA, ⁹ochsner medical center, Metairie, LA, ¹⁰University of Queensland/Ochsner Clinical School, New Orleans, LA, ¹¹Institution of Translational Research, Ochsner Health System, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation and the production of autoantibodies, leading to systemic multiorgan damage. SLE has…
Abstract Number: 2055 • ACR Convergence 2022
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
Alfredo Aguirre¹, Mimi Kim², Kosalaram Goteti³, Ying Li³, Amy Kao⁴, Nathalie Franchimont⁵, George Kong⁵, Catherine Barbey⁶, Qing Zuraw⁷, Robert Gordon⁷, David Manner⁸, Maria Silk⁹, Teodora Staeva¹⁰, Hoang Nguyen¹¹, Richard Furie¹², Matthew Linnik¹³ and Maria Dall'Era¹⁴, ¹University of California, San Francisco, San Francisco, CA, ²Albert Einstein College of Medicine, Larchmont, NY, ³EMD Serono, Boston, MA, ⁴EMD Serono, Billerica, MA, ⁵Biogen, Cambridge, MA, ⁶Biogen, Baar, Switzerland, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Eli Lilly, Carmel, IN, ¹⁰Lupus Research Alliance, New York, NY, ¹¹Lupus Research Alliance, Houston, TX, ¹²Northwell Health, Great Neck, NY, ¹³Eli Lilly and Company, San Diego, CA, ¹⁴University of California, Division of Rheumatology, San Francisco, CA
Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most…
Abstract Number: 2073 • ACR Convergence 2022
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
Laurence S Magder¹, Andrea Fava², Daniel W. Goldman³ and Michelle Petri³, ¹University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
Abstract Number: 2091 • ACR Convergence 2022
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa Parra¹, Jose Meade Aguilar¹, Cynthia Crowson², Cassondra Hulshizer¹, Tina Gunderson¹, Alanna Chamberlain¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: As the life expectancy of patients with systemic lupus erythematosus (SLE) improves, comorbidities have become more critical. Multimorbidity (MM2+) is defined as the coexistence…
Abstract Number: 2184 • ACR Convergence 2022
CaMK4 Controls the Humoral Response via the T Follicular Helper Compartment and Regulates Autoimmunity
Marc Scherlinger¹, Hao Li², Wenliang Pan², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a dysregulated T cell compartment and production of autoantibodies leading to organ damage. We previously identified that…
Abstract Number: 0099 • ACR Convergence 2022
Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis
Lisa Handley¹, Kimberly Lovin Nealy² and Sarah A. Nisly³, ¹Clinical Care Options, Clive, IA, ²Clinical Care Options, Matthews, NC, ³Clinical Care Options, Reston, VA
Background/Purpose: Due to its range of manifestations and lack of specific findings, early diagnosis of SLE is often a challenge, and serious complications, including LN,…
Abstract Number: 0320 • ACR Convergence 2022
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
Shi-Nan Luong¹, Isabella Sheldon², Charles Raine³, Elizabeth Jury³ and Ian Giles³, ¹University College London, United Kingdom and University of New South Wales, Sydney, Australia, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by activation of immunological and cellular pathways, disease flares and adverse pregnancy outcomes (APO). Metabolomic…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
Abstract Number: 0359 • ACR Convergence 2022
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
Ronald Van Vollenhoven¹, Eric F. Morand², Richard A. Furie³, Ian N. Bruce⁴, Gabriel Abreu⁵, Raj Tummala⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁸, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam, Netherlands, ²Monash University, Melbourne, Australia, ³Northwell Health, Great Neck, NY, ⁴The University of Manchester, Manchester, United Kingdom, ⁵AstraZeneca, Mölndal, Sweden, ⁶AstraZeneca, Gaithersburg, MD, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸AstraZeneca, Gothenburg, Sweden
Background/Purpose: In patients with SLE, achieving remission is a treat-to-target goal. Remission is associated with lower rates of hospitalization and damage accrual and better quality…
Abstract Number: 0540 • ACR Convergence 2022
Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Sandra Jägerback¹, Alvaro Gomez¹ and Ioannis Parodis², ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In patients with systemic lupus erythematosus (SLE), renal involvement is associated with high morbidity, and renal flare is a major contributing factor to poor…
Abstract Number: 0642 • ACR Convergence 2022
SLAMF6-SAP Signaling Unit Is Increased in SLE T Follicular Helper Cells
Yevgeniya Gartshteyn¹, Leila Khalili², Adam Mor³ and Anca Askanase², ¹Columbia University Medical Center, Glen Rock, NJ, ²Columbia University Medical Center, New York, NY, ³Columbia University, New York, NY
Background/Purpose: SLE is a multiorgan disease in which immune cells lack self-tolerance resulting in autoimmunity. SLE T cells infiltrate organs, provide help to autoreactive B…
Abstract Number: 0663 • ACR Convergence 2022
Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Zurong Wan², Preetha Balasubramanian³, Juan Rodriguez Alcazar³, Lynnette Walters⁴, Jeanine Baisch², karen onel⁵, Tracey Wright⁶, Virginia Pascual³ and Simone Caielli³, ¹Hospital for Special Surgery/New York Presbyterian-Weill Cornell, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Scottish Rite Hospital for Children, Allen, TX, ⁵Hospital for Special Surgery, New York, NY, ⁶UT Southwestern, Plano, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type 1 interferon signature. It…
Abstract Number: 0827 • ACR Convergence 2022
Unpublished Clinical Trials of Major Rheumatic Diseases
Connor Pedersen¹, Mike Putman², Erin Valley¹, Kathryn Henry³, Ali Duarte-Garcia⁴, Shikha Singla⁵ and Shannon Tai¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin, Manitowoc, WI, ⁴Mayo Clinic, Rochester, MN, ⁵MCW, Fox Point, WI
Background/Purpose: Randomized controlled trials (RCTs) provide high-quality evidence for treatment efficacy, but many RCTs remain unpublished. The objective of this study was to describe the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].